|Articles|November 29, 2022
Real-World Evidence Makes Further Headway in Europe’s Healthcare Planning
Inaugural group of members added to EMA’s new data network focused on RWE.
Advertisement
Europe’s bid to make better use of data in drug research took a step forward late this month with the announcement that the first data partners had been signed up to the new data network of the European Medicines Agency (EMA), DARWIN-EU. Half-a-dozen hospitals, registries, and universities from Finland, France, Estonia, Spain, Netherlands, and the UK have been selected to collaborate in this emerging Data Analysis and Real World Interrogation Network.
The data that DARWIN will be collecting is to be used for studies to generate real-world evidence (RWE) to support scientific evaluations and regulatory decision-making. All the selected partners have access to real-world healthcare data, and will provide DARWIN with results of analyses of these data.
The move enables EMA to initiate the launch of the first three studies to be provided by DARWIN, on blood cancers, on valproate, and on antimicrobial resistance. These studies mark the start of a new phase designed to support regulatory decision-making. The aim is to have 150 such RWE studies per year by 2025. The number of data partners will increase, with a target of adding at least 10 new partners every year.
DARWIN is a federated network that will provide the European medicines regulatory network with access to results from analysis of data from real-world healthcare databases across the EU whenever needed, to support decision-making throughout the life-cycle of a medicine. The network is seen as a pathfinder for the proposed European regulation on health data.
Coincidentally but separately, a drug industry-backed coalition of European health technology assessment (HTA) bodies announced the same day a push for wider use of RWE to support the introduction of new products, particularly cancer treatments and advanced therapies.
At a symposium in Brussels last week, the RWE4Decisions network set out its priorities for expanding RWE use by HTA bodies and payers. Its aim is to promote the sharing of experience of using real-world data (RWD) in outcomes-based managed entry agreements and similar conditional reimbursement processes.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
- Why Clinical Trial Innovations Take Years to Gain Adoption
August 29th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
How Recent Policy Changes Could Impact Clinical Research
3
How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
4
eClinical Technology: Misconceptions, Challenges, and Opportunities
5